Alkaline Phosphatase and Prostate-specific Antigen Response in Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide Alone or in Combination with Radium-223: Ad Hoc Analysis of the PEACE-3 Consortium Trial.
DESIGN, SETTING, AND PARTICIPANTS: Exploratory post hoc analysis of the international, randomised, open-label phase 3 PEACE-3 trial including 446 patients with asymptomatic or mildly symptomatic mCRPC and bone metastases. RESULTS AND LIMITATIONS: At 6 months, confirmed ALP-30 response was 56.5% with the combination versus 50.8% with enzalutamide alone.
DESIGN, SETTING, AND PARTICIPANTS: Exploratory post hoc analysis of the international, randomised, open-label phase 3 PEACE-3 trial including 446 patients with asymptomatic or mildly symptomatic mCRPC and bone metastases. RESULTS AND LIMITATIONS: At 6 months, confirmed ALP-30 response was 56.5% with the combination versus 50.8% with enzalutamide alone.
What the study was
- Study design
- Randomized controlled trial
- Sample size
- 446
- Category
- Other
- Maturity
- Potentially Practice-Changing
- Journal
- European urology oncology
Why it surfaced
High-priority Sentinel scan study: novel treatment potential warrants immediate pipeline escalation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.